Composition of the treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or derivatives thereof

Patent metadata

Field	Value
Publication number	US-9259412-B2
Application number	US-201214354332-A
Country	US
Kind code	B2
Filing date	Oct 24, 2012
Priority date	Oct 25, 2011
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.

First claim

The invention claimed is:

1. A method of treating KCa3.1 channel-mediated disease comprising administering the composition comprising modafinil or derivatives of modafinil having below Chemical Formulas 2 to 5, or pharmaceutically acceptable salts thereof to an individual in need thereof,
wherein the KCa3.1 channel-mediated disease is any one selected from the group consisting of sickle cell anemia;
immune diseases comprising acute immune response or auto-immune diseases;
vascular diseases comprising hypertension, ischemic coronary artery disease, arteriosclerosis, peripheral arterial occlusion, restenosis, atherosclerosis or pulmonary hypertension;
cancers comprising prostate cancer or pancreatic cancer; and
secretory diarrhea

2. The method of claim 1 , the composition further comprising a pharmaceutically acceptable carrier.

3. The method of claim 1 , wherein the composition relaxes vascular smooth muscle by increasing intracellular cAMP concentration.

4. The method of claim 1 , wherein the composition inhibits KCa3.1 channel by increasing intracellular cAMP concentration.

Assignees

• EWHA University—Industry Collaboration Foundation
• Univ Ewha Ind Collaboration

Inventors

• Suh Suk Hyo
• Jung Jae Chul
• Oh Sei Kwan

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A23L33/10

  using additives (addition of substantially indigestible substances A23L33/21) · CPC title

• C07D307/14

  Radicals substituted by nitrogen atoms not forming part of a nitro radical · CPC title

• A61K31/165 Primary

  having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title